1. Pink Sheet
  2. >>Geography
  3. >>North America
  4. >>United States

Avastin, Lucentis Assumed Comparable In DME Absent More Data, MEDCAC Members Say

 
• By Cathy Kelly

In a vote, the panel expressed little confidence in the adequacy of the available evidence on whether there are clinically meaningful differences in outcomes among the anti-VEGF agents.

Efficacy and safety differences between intravitreal anti-VEGF drugs in treating diabetic macular edema (DME) cannot be determined based on existing data, the Medicare Evidence Development and Coverage Advisory Committee concluded at a March 21 meeting.

That means at this point there is no reason to change the assumption that the drugs are equivalent in treating DME, panelists said. The conclusion could undercut arguments that Genentech...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

US FDA’s Familiar Drug Pricing To-Do List

 
• By Michael McCaughan

President Trump’s new Executive Order on drug pricing reprises several policy themes from his first administration, including giving the FDA many tasks intended to increase competition in the marketplace.

US FDA Makary’s Pharma CEO Tour Goes Against Transparency Rhetoric

 
• By Sarah Karlin-Smith

FDA Commissioner Martin Makary will give industry a new avenue for access and influence despite his and HHS Secretary Robert F. Kennedy Jr.’s claims that the pharma-FDA relationship is too cozy.

US Most Favored Nations Policy: Higher Drug Spending In Germany Is ‘Difficult To Imagine’

 
• By Francesca Bruce

Germany’s federal health care decision-making body, the G-BA, tells the Pink Sheet that German drug prices are fair and speculation of price rises in the market due to the US MFN policy is fear mongering.